JP2013522350A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522350A5
JP2013522350A5 JP2013500572A JP2013500572A JP2013522350A5 JP 2013522350 A5 JP2013522350 A5 JP 2013522350A5 JP 2013500572 A JP2013500572 A JP 2013500572A JP 2013500572 A JP2013500572 A JP 2013500572A JP 2013522350 A5 JP2013522350 A5 JP 2013522350A5
Authority
JP
Japan
Prior art keywords
compound
composition
vegf
use according
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013500572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522350A (ja
Filing date
Publication date
Priority claimed from GBGB1004761.1A external-priority patent/GB201004761D0/en
Application filed filed Critical
Publication of JP2013522350A publication Critical patent/JP2013522350A/ja
Publication of JP2013522350A5 publication Critical patent/JP2013522350A5/ja
Pending legal-status Critical Current

Links

JP2013500572A 2010-03-22 2011-03-18 中耳炎の処置において使用するためのソラフェニブもしくはバタラニブなどのｖｅｇｆおよび／またはｈｉｆ経路を標的とする化合物 Pending JP2013522350A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1004761.1A GB201004761D0 (en) 2010-03-22 2010-03-22 Method
GB1004761.1 2010-03-22
PCT/GB2011/000382 WO2011117568A1 (en) 2010-03-22 2011-03-18 Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media

Publications (2)

Publication Number Publication Date
JP2013522350A JP2013522350A (ja) 2013-06-13
JP2013522350A5 true JP2013522350A5 (enExample) 2014-03-06

Family

ID=42228117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013500572A Pending JP2013522350A (ja) 2010-03-22 2011-03-18 中耳炎の処置において使用するためのソラフェニブもしくはバタラニブなどのｖｅｇｆおよび／またはｈｉｆ経路を標的とする化合物

Country Status (8)

Country Link
US (1) US20130078260A1 (enExample)
EP (1) EP2549989A1 (enExample)
JP (1) JP2013522350A (enExample)
CN (1) CN102905697A (enExample)
AU (1) AU2011231405A1 (enExample)
CA (1) CA2793643A1 (enExample)
GB (1) GB201004761D0 (enExample)
WO (1) WO2011117568A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106669A (zh) * 2014-11-04 2017-08-29 南加利福尼亚大学 用于治疗过度表达HIF‑1α的癌症的组合物和方法
BR112020012336A2 (pt) 2017-12-19 2021-03-30 Akouos, Inc. Administração de anticorpos terapêuticos mediada por aav para o ouvido interno
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
CN112807293B (zh) * 2021-03-01 2023-06-02 青岛大学 甲磺酸去铁胺在制备治疗中耳炎药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718624B2 (en) * 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
WO2006083458A2 (en) * 2004-12-30 2006-08-10 Bioresponse Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
US20080051410A1 (en) * 2006-08-02 2008-02-28 Northwestern University Protein Kinase Targeted Therapeutics

Similar Documents

Publication Publication Date Title
TN2013000309A1 (en) Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
JP2018522858A5 (enExample)
HRP20151399T1 (hr) Kinazni inhibitor koji regulira signalni put apoptoze
JP2017537070A5 (enExample)
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
JP2012136541A5 (enExample)
EP4548972A3 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
UA108369C2 (uk) Піролопіримідини як інгібітори cdk4/6
SG10201805033XA (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX2014004559A (es) Derivados de 2-carboxamida cicloamino urea en combinacion con inhibidores de hsp90 para el tratamiento de enfermedades proliferativas.
EA201590457A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201790765A1 (ru) Производные спиродиамина в качестве ингибиторов альдостерон-синтазы
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
JOP20170104A1 (ar) مشتقات فنيل تريازول مستبدلة بأميد واستخدامها
UA112549C2 (uk) Частинки на основі поліакрилату, що містять активну сполуку
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
JP2011219478A5 (enExample)
WO2013142182A3 (en) Combination therapy of a mek inhibitor and igf1r inhibitor
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
WO2013040227A3 (en) Therapeutic compounds
WO2012135697A3 (en) Novel rho kinase inhibitors and methods of use
JP2016530291A5 (enExample)